Connect with us


Oryzon: the Nice&Green Fund Requests a Conversion of Obligations for €1.8 Million

Oryzon plans to maintain its share capital at €3.03 million and seek admission for new shares on Madrid, Barcelona, Bilbao, and Valencia Stock Exchanges. The biopharmaceutical company reduced H1 losses by 56%, totaling €568,224, with an Ebitda of €2.4 million. Oryzon focuses on epigenetics-based therapies for cancer and neurodegenerative disorders.




The private equity investment company Nice&Green has requested from the Spanish biopharmaceutical company Oryzon Genomics a conversion of debentures for a joint nominal amount of €1.8 million, at an exchange price of €2.0973 per share, which represents 858,246 titles with a nominal value of €0.05 each.

Consequently, for the purposes of carrying out the conversion, the company has informed the National Securities Market Commission (CNMV) this Thursday that it will proceed to increase its share capital by a total nominal amount of €42,912.30, through the issuance and placing in circulation of 858,246 new ordinary shares of €0.05 par value each .

The new Oryzon shares will be issued with an issue rate of €2.0973 per share (€0.05 of nominal value plus €2.0473 of share premium), with the total share premium of €1.76 million and the effective amount (nominal plus premium) of the capital increase of €1.8 million.

After the aforementioned capital increase, the company’s share capital will be set at the amount of €3.03 million, represented by 60,573,570 shares with a nominal value of €0.05 each.

Read more about Oryzon and find the latest financial news of the day with our companion app. The Born2Invest mobile app is available for free for both Android and iOS devices, and keeps its readers up to date with the most important market updates.

Oryzon will leave its share capital set at the amount of €3.03 million

The biopharmaceutical company will request admission to trading of the new shares issued on the Madrid, Barcelona, ​​Bilbao and Valencia Stock Exchanges , through the Stock Exchange Interconnection System (Continuous Market).

Oryzon ended the first half of the year reducing its losses by 56%, to €568,224. The company’s gross operating result (Ebitda) was €2.4 million, 25% less than in the first half of 2022 . Oryzon’s research and development (R&D) sales increased by 2%, reaching €7.9 million until June.

Clinical-stage biopharmaceuticals discover and develop epigenetics-based therapies for cancer patients and neurodegenerative disorders . Although the company was established in 2000, it has been listed on the stock market since 2015. Carlos Buesa Arjol has been the president and CEO of Oryzon Genomics since its founding.


(Featured image by PIX1861 via Pixabay)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in PlantaDoce. A third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.

Eva Wesley is an experienced journalist, market trader, and financial executive. Driven by excellence and a passion to connect with people, she takes pride in writing think pieces that help people decide what to do with their investments. A blockchain enthusiast, she also engages in cryptocurrency trading. Her latest travels have also opened her eyes to other exciting markets, such as aerospace, cannabis, healthcare, and telcos.